

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Martin MULLER et al.)	Prior Group Art Unit: 1648
)	
Prior Application No.: 10/340,783)	Prior Examiner: A. Salimi
)	
Filed: Concurrently herewith)	
)	
For: ANTIBODIES SPECIFIC FOR)	
SEROREACTIVE REGIONS ON)	
HPV 16 PROTEINS E1 AND E2)	
Commissioner for Patents		
P.O. Box 1450		
Alexandria, VA 22313-1450		

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed with the above-referenced application.

Copies of the listed documents were previously submitted or cited by the Examiner in prior applications Serial No. 10/340,783, filing date January 13, 2003, Serial No. 09/758,318, filing date January 12, 2001, and Serial No. 08/468,337, filing date June 6, 1995, upon which applicants rely for the benefits provided in 35 U.S.C. § 120. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 17, 2004

By: Carol P. Einaudi
Carol P. Einaudi
Reg. No. 32,220

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	05552.1199-05000	Appln. No.	
Applicant	Martin MULLER et al.		
Filing Date	March 17, 2004	Group:	

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
		4,554,101	11/1985	Hopp			
		5,180,806	01/1993	Dillner et al.			

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
		0,344,940 A2	12/1989	EPO			
		0,257,754 A2	03/1988	EPO			
		91/18294	11/1991	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	J. Dillner, Mapping of Linear Epitopes of Human Papillomavirus Type 16: the E1, E2, E4, E5, E6 and E7 Open Reading Frames, Int. J. Cancer, 46:703-711 (1990).
	A.J. Cumber et al., Preparation of Antibody-Toxin Conjugates, Methods in Enzymology, 112:207-225 (1985).
	M. Duerst et al., A Papilloma DNA From a Cervical Carcinoma and its Prevalence in Cancer Biopsy Samples from Different Geographic Regions, Proc. Natl. Acad. Sci. USA, 80:3812-3815 (1983).
	E.M. Lees et al., The E2 Protein of Human Papillomavirus Type 16, Eur. J. Biochem., 190:85-92 (1990).
	J. M. Gauthier et al., Structural Analysis of the Human Papillomavirus Type 16-E2 Transactivator with Antipeptide Antibodies Reveals a High Mobility Region Linking the Transactivation and the DNA-Binding Domains, Nucl. Acid Res. 19(25):7073-7079 (1991).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	05552.1199-05000	Appln. No.	
Applicant	Martin MULLER et al.		
Filing Date	March 17, 2004	Group:	

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	J. Dillner et al., PNAS USA 86:3838-3841 (May 1989).
	R.W. Ellis, New Technologies for Making Vaccines, 568-575 (1988).
	K. Seedorf et al., Human Papillomavirus Type 16 DNA Sequence, Virology 145:181-185 (1985).
	G. Smith, Filamentous Fusion Phage: Novel Expression Vectors that Displayed Cloned Antigens on the Virion Surface, Science, 228:1315-1316 (1985).
	G. Smith, Filamentous Phage as Cloning Vectors, Survey of the Uses of F1 Phage Vectors, 3:61-83 (1987).
	J. Crissman et al., Gene-III Protein of Filamentous Phages: Evidence for a Carboxyl-Terminal Domain with a Role in Morphogenesis, Virology 132:445-455 (1984).
	K. Seedorf et al., Identification of Early Proteins of the Human Papilloma Viruses Type 16 (HPV 16) and Type 18 (HPV 18) in Cervical Carcinoma Cells, The EMBO Journal 6(1):139-144 (1987).
	E. Remaut et al., Plasmid Vectors for the High-Efficiency Expression Controlled by the PL Promoter of Coliphage Lambda, Gene 15:81-93 (1981).
	L. Lyons et al., The Genetic Map of Filamentous Bacteriophage f1, Virology 49:45-60 (1972).
	Kochel et al., Virology 182:644-654 (1991).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce